Selected Publications
(See all Fred Krebs' publications in PubMed.)
“Apical Application of “Nanosecond-pulsed dielectric barrier discharge plasma causes the basolateral release of adenosine triphosphate as a damage-associated molecular pattern from polarized HaCaT cells”
Truong B, K Siegert, A Lin, V Miller, and FC Krebs
Plasma Medicine, 7: 117-131, 2017
“Specific amino acids in HIV-1 Vpr are significantly associated with differences in patient neurocognitive status”
Dampier W, GC Antell, B Aiamkitsumrit, MR Nonnemacher, JM Jacobson, V Pirrone, W Zhong, K Kercher, S Passic, JW Williams, T James, KN Devlin, T Giovannetti, DJ Libon, Z Szep, GD Ehrlich, B Wigdahl, and FC Krebs
J Neurovirol, 23:113-124, 2017
“Evidence of divergent amino acid usage in comparative analyses of R5- and X4-associated HIV-1 Vpr sequences”
Antell GC, W Dampier, B Aiamkitsumrit, MR Nonnemacher, V Pirrone, W Zhong, K Kercher, S Passic, J Williams, Y Liu, T James, JM Jacobson, Z Szep, B Wigdahl, and FC Krebs
Int J Genomics, 2017:4081585, 2017
“Variability in human semen content and its potential effects in the female reproductive tract”
Keogan S, K Siegert, B Wigdahl, and FC Krebs
Journal of Reproductive Biology and Health, 4: 1, 2016
“Defining the roles for Vpr in HIV-1-associated neuropathogenesis”
James T, MR Nonnemacher, B Wigdahl, and FC Krebs
J Neurovirol, 22:403-415, 2016
“cAMP signaling enhances HIV-1 long terminal repeat (LTR)-directed transcription and viral replication in bone marrow progenitor cells”
Banerjee A, L Li, V Pirrone, FC Krebs, B Wigdahl, and MR Nonnemacher
Clin Med Insights Pathol,10: 1179555717694535, 2016
“Utilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signatures”
Antell GC, W Dampier, B Aiamkitsumrit, MR Nonnemacher, JM Jacobson, V Pirrone, W Zhong, K Kercher, S Passic, JW Williams, G Schwartz, U Hershberg, FC Krebs, and B Wigdahl
Retrovirology, 13: 32, 2016
“Critical Review: Immunomodulation by seminal factors and implications for male-to-female HIV-1 transmission
Keogan S, K Siegert, B Wigdahl, and FC Krebs
J Acquir Immune Defic Syndr, 69:131-137, 2015
"Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1"
Pirrone V, Passic S, Wigdahl B, and FC Krebs
Virol J, 9: 33, 2012.
"Antiviral breadth and combination potential of peptide triazole HIV-1 entry inhibitors"
McFadden K, Fletcher P, Rossi F, Kantharaju, Umashankara M, Pirrone V, Rajagopal S, Gopi H, Krebs FC, Martin-Garcia J, Shattock RJ, and I Chaiken
Antimicrob Agents Chemother, 56: 1073-1080, 2012.
"Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety"
Lozenski K, Ownbey R, Wigdahl B, Kish-Catalone T, and FC Krebs
BMC Pharmacology & Toxicology, 13: 9, 2012.
"Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid"
Kortagere S, Madani N, Mankowski MK, Schon A, Zentner I, Swaminathan G, Princiotto A, Anthony K, Oza A, Sierra LJ, Passic SR, Wang X, Jones DM, Stavale E, Krebs FC, Martin-Garcia J, Freire E, Ptak RG, Sodroski J, Cocklin S, and AB Smith III
J Virol, 86: 8472-8481, 2012.
"Infection by CXCR4-tropic human immunodeficiency virus type 1 Is inhibited by the cationic cell-penetrating peptide derived from HIV-1 Tat"
Keogan S, Passic S, and FC Krebs
Int J Pept, 2012: 349427, 2012.
"A nipple shield delivery system for oral drug delivery to breastfeeding infants: microbicide delivery to inactivate HIV"
Gerrard SE, Baniecki ML, Sokal DC, Morris MK, Urdaneta-Hartmann S, Krebs FC, Wigdahl B, Abrams BF, Hanson CV, Slater NK, and AD Edwards
Int J Pharm, 434: 224-234, 2012.
"The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1"
Pirrone V, Wigdahl B, and Krebs FC
Antiviral Research, 90(3): 168-182, 2011